Using nirmatrelvir/ritonavir in patients with epilepsy: An update from the Israeli chapter of the International League Against Epilepsy

Presented herein are recommendations for use of nirmatrelvir/ritonavir in patients with epilepsy, as issued by the Steering Committee of the Israeli chapter of the International League Against Epilepsy. The recommendations suggest that patients on moderate‐to‐strong enzyme‐inducing antiseizure medic...

Descripción completa

Detalles Bibliográficos
Autores principales: Noyman, Iris, Ekstein, Dana, Fahoum, Firas, Herskovitz, Moshe, Linder, Ilan, Ben Zeev, Bruria, Eyal, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314867/
https://www.ncbi.nlm.nih.gov/pubmed/35239193
http://dx.doi.org/10.1111/epi.17212
_version_ 1784754421552381952
author Noyman, Iris
Ekstein, Dana
Fahoum, Firas
Herskovitz, Moshe
Linder, Ilan
Ben Zeev, Bruria
Eyal, Sara
author_facet Noyman, Iris
Ekstein, Dana
Fahoum, Firas
Herskovitz, Moshe
Linder, Ilan
Ben Zeev, Bruria
Eyal, Sara
author_sort Noyman, Iris
collection PubMed
description Presented herein are recommendations for use of nirmatrelvir/ritonavir in patients with epilepsy, as issued by the Steering Committee of the Israeli chapter of the International League Against Epilepsy. The recommendations suggest that patients on moderate‐to‐strong enzyme‐inducing antiseizure medications (ASMs) and everolimus should not be treated with nirmatrelvir/ritonavir; rectal diazepam may be used as an alternative to buccal midazolam; doses of ASMs that are cytochrome P450 (CYP3A4) substrates might be adjusted; and patients treated with combinations of nirmatrelvir/ritonavir and ASMs that are CYP3A4 substrates or lamotrigine should be monitored for drug efficacy and adverse drug reactions.
format Online
Article
Text
id pubmed-9314867
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93148672022-07-30 Using nirmatrelvir/ritonavir in patients with epilepsy: An update from the Israeli chapter of the International League Against Epilepsy Noyman, Iris Ekstein, Dana Fahoum, Firas Herskovitz, Moshe Linder, Ilan Ben Zeev, Bruria Eyal, Sara Epilepsia Commentary Presented herein are recommendations for use of nirmatrelvir/ritonavir in patients with epilepsy, as issued by the Steering Committee of the Israeli chapter of the International League Against Epilepsy. The recommendations suggest that patients on moderate‐to‐strong enzyme‐inducing antiseizure medications (ASMs) and everolimus should not be treated with nirmatrelvir/ritonavir; rectal diazepam may be used as an alternative to buccal midazolam; doses of ASMs that are cytochrome P450 (CYP3A4) substrates might be adjusted; and patients treated with combinations of nirmatrelvir/ritonavir and ASMs that are CYP3A4 substrates or lamotrigine should be monitored for drug efficacy and adverse drug reactions. John Wiley and Sons Inc. 2022-03-09 2022-05 /pmc/articles/PMC9314867/ /pubmed/35239193 http://dx.doi.org/10.1111/epi.17212 Text en © 2022 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Commentary
Noyman, Iris
Ekstein, Dana
Fahoum, Firas
Herskovitz, Moshe
Linder, Ilan
Ben Zeev, Bruria
Eyal, Sara
Using nirmatrelvir/ritonavir in patients with epilepsy: An update from the Israeli chapter of the International League Against Epilepsy
title Using nirmatrelvir/ritonavir in patients with epilepsy: An update from the Israeli chapter of the International League Against Epilepsy
title_full Using nirmatrelvir/ritonavir in patients with epilepsy: An update from the Israeli chapter of the International League Against Epilepsy
title_fullStr Using nirmatrelvir/ritonavir in patients with epilepsy: An update from the Israeli chapter of the International League Against Epilepsy
title_full_unstemmed Using nirmatrelvir/ritonavir in patients with epilepsy: An update from the Israeli chapter of the International League Against Epilepsy
title_short Using nirmatrelvir/ritonavir in patients with epilepsy: An update from the Israeli chapter of the International League Against Epilepsy
title_sort using nirmatrelvir/ritonavir in patients with epilepsy: an update from the israeli chapter of the international league against epilepsy
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314867/
https://www.ncbi.nlm.nih.gov/pubmed/35239193
http://dx.doi.org/10.1111/epi.17212
work_keys_str_mv AT noymaniris usingnirmatrelvirritonavirinpatientswithepilepsyanupdatefromtheisraelichapteroftheinternationalleagueagainstepilepsy
AT eksteindana usingnirmatrelvirritonavirinpatientswithepilepsyanupdatefromtheisraelichapteroftheinternationalleagueagainstepilepsy
AT fahoumfiras usingnirmatrelvirritonavirinpatientswithepilepsyanupdatefromtheisraelichapteroftheinternationalleagueagainstepilepsy
AT herskovitzmoshe usingnirmatrelvirritonavirinpatientswithepilepsyanupdatefromtheisraelichapteroftheinternationalleagueagainstepilepsy
AT linderilan usingnirmatrelvirritonavirinpatientswithepilepsyanupdatefromtheisraelichapteroftheinternationalleagueagainstepilepsy
AT benzeevbruria usingnirmatrelvirritonavirinpatientswithepilepsyanupdatefromtheisraelichapteroftheinternationalleagueagainstepilepsy
AT eyalsara usingnirmatrelvirritonavirinpatientswithepilepsyanupdatefromtheisraelichapteroftheinternationalleagueagainstepilepsy

Ejemplares similares